In the UK business, we are interested in making ... Earlier this year we obtained the license for Libtayo which is one of our newer oncology medicines for advanced cutaneous squamous cell carcinoma.

A ~$4.5B share repurchase program adds further value. LIBTAYO demonstrated massive growth, accelerating to 50% in Q4 2024 versus Q4 2023. Approval in CSCC means that this growth catalyst is ...

Bitpanda receives FCA approval to expand in the UK. This allows the exchange to offer crypto trading, staking, savings plans ...

Test lays the groundwork for development of Perenco’s 40 million tonne per annum Poseidon carbon capture and storage project, ...

In the fourth quarter of 2024, Libtayo grew sales 50% to $367 million, propelling the PD-1 treatment past the blockbuster threshold for the first time. During the full year, the drug's sales reach ...

Crypto.com has obtained authorization to provide cross-border crypto asset services across all EEA Member States. The company ...

Bitpanda has received approval from the Financial Conduct Authority to offer more than 500 crypto assets in the United ...

Regeneron Pharmaceuticals, Inc. announced positive results from the phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically ...

The supply agreement supports the evaluation of Immuneering’s lead product candidate, IMM-1-104, in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports ...